Basic Stats
| LEI | 549300N33TFDZHS81H11 |
| CIK | 1479290 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Revance Therapeutics, Inc.
SEC Filings (Chronological Order)
This page provides a complete, chronological list of SEC Filings, excluding ownership filings which we provide elsewhere.
| February 18, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 15 CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. Commission File Number: 001-36297 Revance Therapeutics, Inc. (Exact name of registrant as specified |
|
| February 13, 2025 |
AGREEMENT REGARDING JOINT FILING OF STATEMENT ON SCHEDULE 13D OR 13G EX-99 2 exhibitajointfilingagreement.htm EXHIBIT A AGREEMENT REGARDING JOINT FILING OF STATEMENT ON SCHEDULE 13D OR 13G The undersigned agree to file jointly with the Securities and Exchange Commission (the "SEC") any and all statements on Schedule 13D or Schedule 13G (and any amendments or supplements thereto) required under section 13(d) of the Securities Exchange Act of 1934, as amended, in con |
|
| February 12, 2025 |
Registration No. 333-193963 Registration No. 333-198499 Registration No. 333-203235 Registration No. 333-208543 Registration No. 333-209949 Registration No. 333-216342 Registration No. 333-223433 Registration No. 333-229977 Registration No. 333-235994 Registration No. 333-240061 Registration No. 333-252526 Registration No. 333-263099 Registration No. 333-270130 Registration No. 333-277490 UNITED S |
|
| February 12, 2025 |
Registration No. 333-193963 Registration No. 333-198499 Registration No. 333-203235 Registration No. 333-208543 Registration No. 333-209949 Registration No. 333-216342 Registration No. 333-223433 Registration No. 333-229977 Registration No. 333-235994 Registration No. 333-240061 Registration No. 333-252526 Registration No. 333-263099 Registration No. 333-270130 Registration No. 333-277490 UNITED S |
|
| February 12, 2025 |
Registration No. 333-193963 Registration No. 333-198499 Registration No. 333-203235 Registration No. 333-208543 Registration No. 333-209949 Registration No. 333-216342 Registration No. 333-223433 Registration No. 333-229977 Registration No. 333-235994 Registration No. 333-240061 Registration No. 333-252526 Registration No. 333-263099 Registration No. 333-270130 Registration No. 333-277490 UNITED S |
|
| February 12, 2025 |
Registration No. 333-193963 Registration No. 333-198499 Registration No. 333-203235 Registration No. 333-208543 Registration No. 333-209949 Registration No. 333-216342 Registration No. 333-223433 Registration No. 333-229977 Registration No. 333-235994 Registration No. 333-240061 Registration No. 333-252526 Registration No. 333-263099 Registration No. 333-270130 Registration No. 333-277490 UNITED S |
|
| February 12, 2025 |
Registration No. 333-193963 Registration No. 333-198499 Registration No. 333-203235 Registration No. 333-208543 Registration No. 333-209949 Registration No. 333-216342 Registration No. 333-223433 Registration No. 333-229977 Registration No. 333-235994 Registration No. 333-240061 Registration No. 333-252526 Registration No. 333-263099 Registration No. 333-270130 Registration No. 333-277490 UNITED S |
|
| February 12, 2025 |
Registration No. 333-193963 Registration No. 333-198499 Registration No. 333-203235 Registration No. 333-208543 Registration No. 333-209949 Registration No. 333-216342 Registration No. 333-223433 Registration No. 333-229977 Registration No. 333-235994 Registration No. 333-240061 Registration No. 333-252526 Registration No. 333-263099 Registration No. 333-270130 Registration No. 333-277490 UNITED S |
|
| February 12, 2025 |
Registration No. 333-193963 Registration No. 333-198499 Registration No. 333-203235 Registration No. 333-208543 Registration No. 333-209949 Registration No. 333-216342 Registration No. 333-223433 Registration No. 333-229977 Registration No. 333-235994 Registration No. 333-240061 Registration No. 333-252526 Registration No. 333-263099 Registration No. 333-270130 Registration No. 333-277490 UNITED S |
|
| February 12, 2025 |
Registration No. 333-193963 Registration No. 333-198499 Registration No. 333-203235 Registration No. 333-208543 Registration No. 333-209949 Registration No. 333-216342 Registration No. 333-223433 Registration No. 333-229977 Registration No. 333-235994 Registration No. 333-240061 Registration No. 333-252526 Registration No. 333-263099 Registration No. 333-270130 Registration No. 333-277490 UNITED S |
|
| February 12, 2025 |
Registration No. 333-193963 Registration No. 333-198499 Registration No. 333-203235 Registration No. 333-208543 Registration No. 333-209949 Registration No. 333-216342 Registration No. 333-223433 Registration No. 333-229977 Registration No. 333-235994 Registration No. 333-240061 Registration No. 333-252526 Registration No. 333-263099 Registration No. 333-270130 Registration No. 333-277490 UNITED S |
|
| February 12, 2025 |
Registration No. 333-193963 Registration No. 333-198499 Registration No. 333-203235 Registration No. 333-208543 Registration No. 333-209949 Registration No. 333-216342 Registration No. 333-223433 Registration No. 333-229977 Registration No. 333-235994 Registration No. 333-240061 Registration No. 333-252526 Registration No. 333-263099 Registration No. 333-270130 Registration No. 333-277490 UNITED S |
|
| February 12, 2025 |
Registration No. 333-193963 Registration No. 333-198499 Registration No. 333-203235 Registration No. 333-208543 Registration No. 333-209949 Registration No. 333-216342 Registration No. 333-223433 Registration No. 333-229977 Registration No. 333-235994 Registration No. 333-240061 Registration No. 333-252526 Registration No. 333-263099 Registration No. 333-270130 Registration No. 333-277490 UNITED S |
|
| February 12, 2025 |
Registration No. 333-275548 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-3ASR REGISTRATION STATEMENT NO. 333-275548 UNDER THE SECURITIES ACT OF 1933 REVANCE THERAPEUTICS, INC. (Exact name of Registrant as specified in its charter) Delaware 77-0551645 (State or jurisdiction of incorporation or organization) (I.R.S. Employer Identif |
|
| February 12, 2025 |
Registration No. 333-193963 Registration No. 333-198499 Registration No. 333-203235 Registration No. 333-208543 Registration No. 333-209949 Registration No. 333-216342 Registration No. 333-223433 Registration No. 333-229977 Registration No. 333-235994 Registration No. 333-240061 Registration No. 333-252526 Registration No. 333-263099 Registration No. 333-270130 Registration No. 333-277490 UNITED S |
|
| February 12, 2025 |
Registration No. 333-193963 Registration No. 333-198499 Registration No. 333-203235 Registration No. 333-208543 Registration No. 333-209949 Registration No. 333-216342 Registration No. 333-223433 Registration No. 333-229977 Registration No. 333-235994 Registration No. 333-240061 Registration No. 333-252526 Registration No. 333-263099 Registration No. 333-270130 Registration No. 333-277490 UNITED S |
|
| February 12, 2025 |
S-8 POS Registration No. 333-193963 Registration No. 333-198499 Registration No. 333-203235 Registration No. 333-208543 Registration No. 333-209949 Registration No. 333-216342 Registration No. 333-223433 Registration No. 333-229977 Registration No. 333-235994 Registration No. 333-240061 Registration No. 333-252526 Registration No. 333-263099 Registration No. 333-270130 Registration No. 333-277490 |
|
| February 6, 2025 |
Exhibit 4.1 FIRST SUPPLEMENTAL INDENTURE FIRST SUPPLEMENTAL INDENTURE (this “First Supplemental Indenture”), dated as of February 6, 2025, between Revance Therapeutics, Inc., a Delaware corporation (the “Issuer”), and U.S. Bank Trust Company, National Association (as successor in interest to U.S. Bank National Association), a national banking association, as trustee (the “Trustee”), supplementing |
|
| February 6, 2025 |
AMENDED AND RESTATED BYLAWS REVANCE THERAPEUTICS, INC. A Delaware Corporation ARTICLE I EX-3.2 Exhibit 3.2 AMENDED AND RESTATED BYLAWS OF REVANCE THERAPEUTICS, INC. A Delaware Corporation ARTICLE I OFFICES Section 1. Registered Office. The registered office of Revance Therapeutics, Inc. (the “Corporation”) shall be located at 251 Little Falls Drive, Wilmington, New Castle County, Delaware 19808. The name of the Corporation’s registered agent at such address shall be Corporation Servi |
|
| February 6, 2025 |
AMENDED AND RESTATED CERTIFICATE OF INCORPORATION REVANCE THERAPEUTICS, INC. ARTICLE ONE Exhibit 3.1 AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF REVANCE THERAPEUTICS, INC. ARTICLE ONE The name of the corporation is Revance Therapeutics, Inc. (hereinafter called the “Corporation”). ARTICLE TWO The address of the Corporation’s registered office in the State of Delaware is 251 Little Falls Drive, Wilmington, New Castle County, Delaware 19808. The name of its registered agent at |
|
| February 6, 2025 |
Exhibit 99.1 Crown Laboratories Announces Completion of Acquisition of Revance Therapeutics The business combination reinforces Crown’s position as a leading, innovative, high-growth aesthetics and skincare company Johnson City, Tenn. – February 6, 2025 — Crown Laboratories, Inc. (“Crown”), a privately held, global innovative leader in the skincare industry, today announced the successful closing |
|
| February 6, 2025 |
Form 25 |
|
| February 6, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 6, 2025 Revance Therapeutics, Inc. (Exact name of registrant as specified in charter) Delaware 001-36297 77-0551645 (State or other jurisdiction of incorporation) (Commission |
|
| February 5, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(d)(1) OR 13(e)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 5) REVANCE THERAPEUTICS, INC. (Name of Subject Company (issuer)) REBA MERGER SUB, INC. (Offeror) a wholly-owned subsidiary of CROWN LABORATORIES, INC. (Parent of Offeror) CROWN HOLDINGS INTERCO LLC (Other |
|
| February 5, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Rule 14d-101) Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 (Amendment No. 7) Revance Therapeutics, Inc. (Name of Subject Company) Revance Therapeutics, Inc. (Name of Persons Filing Statement) Common Stock, par value $0.001 per share (Title of Class of Secur |
|
| February 5, 2025 |
Crown Laboratories and Revance Therapeutics Announce Expiration of Tender Offer Exhibit (a)(5)(P) Crown Laboratories and Revance Therapeutics Announce Expiration of Tender Offer Johnson City, Tenn. |
|
| January 31, 2025 |
Exhibit(a)(5)(O) Revance Stockholders Urged to Tender Their Shares in Support of Crown Transaction by the February 4th Deadline • Crown offer of $3. |
|
| January 31, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Rule 14d-101) Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 (Amendment No. 6) Revance Therapeutics, Inc. (Name of Subject Company) Revance Therapeutics, Inc. (Name of Persons Filing Statement) Common Stock, par value $0.001 per share (Title of Class of Secur |
|
| January 31, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(d)(1) OR 13(e)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 4) REVANCE THERAPEUTICS, INC. (Name of Subject Company (issuer)) REBA MERGER SUB, INC. (Offeror) a wholly-owned subsidiary of CROWN LABORATORIES, INC. (Parent of Offeror) CROWN HOLDINGS INTERCO LLC (Other |
|
| January 31, 2025 |
Exhibit (a)(5)(E) Revance Stockholders Urged to Tender Their Shares in Support of Crown Transaction by the February 4th Deadline • Crown offer of $3. |
|
| January 21, 2025 |
AMENDMENT NO. 2 TO THE AMENDED AND RESTATED AGREEMENT AND PLAN OF MERGER Exibit 2.1 Execution Version AMENDMENT NO. 2 TO THE AMENDED AND RESTATED AGREEMENT AND PLAN OF MERGER This AMENDMENT NO. 2 TO THE AMENDED AND RESTATED AGREEMENT AND PLAN OF MERGER is made and entered into as of January 17, 2025 (this “Amendment No. 2”), by and among Crown Laboratories, Inc., a Delaware corporation (“Parent”), Reba Merger Sub, Inc., a Delaware corporation and wholly owned subsidiar |
|
| January 21, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Rule 14d-101) Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 (Amendment No. 5) Revance Therapeutics, Inc. (Name of Subject Company) Revance Therapeutics, Inc. (Name of Persons Filing Statement) Common Stock, par value $0.001 per share (Title of Class of Secur |
|
| January 21, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(d)(1) OR 13(e)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 3) REVANCE THERAPEUTICS, INC. (Name of Subject Company (issuer)) REBA MERGER SUB, INC. (Offeror) a wholly-owned subsidiary of CROWN LABORATORIES, INC. (Parent of Offeror) CROWN HOLDINGS INTERCO LLC (Other |
|
| January 21, 2025 |
Exhibit (a)(5)(N) Crown Laboratories and Revance Amend the A&R Merger Agreement to Increase Offer Price to $3. |
|
| January 21, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 17, 2025 (January 17, 2025) Revance Therapeutics, Inc. (Exact name of registrant as specified in charter) Delaware 001-36297 77-0551645 (State or other jurisdiction of incorpo |
|
| January 21, 2025 |
Exhibit 107 Calculation of Filing Fee Tables Schedule TO REVANCE THERAPEUTICS, INC. |
|
| January 21, 2025 |
Exhibit (d)(12) Execution Version Hildred Perennial Partners I, LP Hildred Capital Co-Invest-REBA, LP Hildred Equity Partners III, LP Hildred Equity Partners III-A Hildred Equity Partners III-B January 17, 2025 Crown Laboratories, Inc. |
|
| January 21, 2025 |
AMENDMENT NO. 2 TO THE AMENDED AND RESTATED AGREEMENT AND PLAN OF MERGER Exhibit (d)(11) Execution Version AMENDMENT NO. 2 TO THE AMENDED AND RESTATED AGREEMENT AND PLAN OF MERGER This AMENDMENT NO. 2 TO THE AMENDED AND RESTATED AGREEMENT AND PLAN OF MERGER is made and entered into as of January 17, 2025 (this “Amendment No. 2”), by and among Crown Laboratories, Inc., a Delaware corporation (“Parent”), Reba Merger Sub, Inc., a Delaware corporation and wholly owned subs |
|
| January 21, 2025 |
Exhibit 99.1 Crown Laboratories and Revance Amend the A&R Merger Agreement to Increase Offer Price to $3.65 per Share and Extend Existing Tender Offer • Increased offer price to $3.65 per share, a $0.55 per share increase • Improved offer unanimously approved by Revance Board of Directors • Crown to extend tender offer until 11:59 p.m., Eastern Time, on February 4, 2025 • Crown’s offer is the only |
|
| January 21, 2025 |
SECOND AMENDED AND RESTATED LIMITED GUARANTEE Exhibit (d)(13) Execution Version SECOND AMENDED AND RESTATED LIMITED GUARANTEE This Second Amended and Restated Limited Guarantee, dated as of January 17, 2025 (this “Limited Guarantee”), by Hildred Perennial Partners I, LP, Hildred Capital Co-Invest-REBA, LP, Hildred Equity Partners III, LP, Hildred Equity Partners III-A, LP and Hildred Equity Partners III-B, LP, each a Delaware limited partnership (each of the foregoing, a “Guarantor” and collectively, the “Guarantors”), is made in favor of Revance Therapeutics, Inc. |
|
| January 17, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Rule 14d-101) Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 (Amendment No. 4) Revance Therapeutics, Inc. (Name of Subject Company) Revance Therapeutics, Inc. (Name of Persons Filing Statement) Common Stock, par value $0.001 per share (Title of Class of Secur |
|
| January 13, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(d)(1) OR 13(e)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 2) REVANCE THERAPEUTICS, INC. (Name of Subject Company (issuer)) REBA MERGER SUB, INC. (Offeror) a wholly-owned subsidiary of CROWN LABORATORIES, INC. (Parent of Offeror) CROWN HOLDINGS INTERCO LLC (Other |
|
| January 13, 2025 |
Crown Laboratories Extension of Tender Offer to Acquire Revance Therapeutics, Inc. Exhibit (a)(5)(M) Crown Laboratories Extension of Tender Offer to Acquire Revance Therapeutics, Inc. |
|
| January 13, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Rule 14d-101) Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 (Amendment No. 3) Revance Therapeutics, Inc. (Name of Subject Company) Revance Therapeutics, Inc. (Name of Persons Filing Statement) Common Stock, par value $0.001 per share (Title of Class of Secur |
|
| January 10, 2025 |
AGREEMENT REGARDING JOINT FILING OF STATEMENT ON SCHEDULE 13D OR 13G EXHIBIT 99.1 AGREEMENT REGARDING JOINT FILING OF STATEMENT ON SCHEDULE 13D OR 13G The undersigned agree to file jointly with the Securities and Exchange Commission (the “SEC”) any and all statements on Schedule 13D or Schedule 13G or Forms 3, 4 or 5(and any amendments or supplements thereto) required under section 13(d) and 16(a) of the Securities Exchange Act of 1934, as amended, in connection wi |
|
| January 8, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Rule 14d-101) Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 (Amendment No. 2) Revance Therapeutics, Inc. (Name of Subject Company) Revance Therapeutics, Inc. (Name of Persons Filing Statement) Common Stock, par value $0.001 per share (Title of Class of Secur |
|
| January 8, 2025 |
Crown Laboratories, Inc. 207 Mockingbird Lane Johnson City, Tennessee 37604 Exhibit 99.1 CONFIDENTIAL Crown Laboratories, Inc. 207 Mockingbird Lane Johnson City, Tennessee 37604 January 6, 2025 Board of Directors Revance Therapeutics, Inc. 1222 Demonbreun Street Nashville, Tennessee 37203 To the Members of the Board of Directors: We strongly believe that the incomplete, non-binding and highly contingent “proposal” of Teoxane SA (“Teoxane”), dated January 6, 2025 (the “Teo |
|
| January 6, 2025 |
Exhibit 99.1 CONFIDENTIAL January 6, 2025 Angus C. Russell Chairman & Mark Foley Chief Executive Officer Revance Therapeutics, Inc. 1222 Demonbreun St., 20th Floor Nashville, TN 37203 USA Dear Messrs. Russell & Foley, Teoxane SA is pleased to submit this proposal (“Proposal”) to acquire all of the outstanding shares of of Revance Therapeutics, Inc. (“Revance” or the “Company”), other than the shar |
|
| January 6, 2025 |
Exhibit 99.2 FOR RELEASE AT 9:00 AM ET ON JANUARY 6, 2025 Teoxane SA Announces Superior Proposal to Acquire Revance Therapeutics for $3.60 per Share in Cash Compelling Cash Proposal Provides 16% Premium Over Revance’s Amended and Restated Agreement with Crown Laboratories GENEVA, January 6, 2025 – Teoxane SA today announced that on January 6, 2025, it submitted a proposal to the Board of Directors |
|
| January 2, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Rule 14d-101) Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 (Amendment No. 1) Revance Therapeutics, Inc. (Name of Subject Company) Revance Therapeutics, Inc. (Name of Persons Filing Statement) Common Stock, par value $0.001 per share (Title of Class of Secur |
|
| January 2, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(d)(1) OR 13(e)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 1) REVANCE THERAPEUTICS, INC. (Name of Subject Company (issuer)) REBA MERGER SUB, INC. (Offeror) a wholly-owned subsidiary of CROWN LABORATORIES, INC. (Parent of Offeror) CROWN HOLDINGS INTERCO LLC (Other |
|
| January 2, 2025 |
ARES CAPITAL MANAGEMENT LLC 245 Park Avenue, 44th Floor New York, NY 10167 EX-99.(B)(1) Exhibit (b)(1) Execution Version CONFIDENTIAL ARES CAPITAL MANAGEMENT LLC 245 Park Avenue, 44th Floor New York, NY 10167 December 7, 2024 Crown Laboratories Holdings, Inc. c/o Hildred Capital Management, LLC 745 Fifth Avenue Suite 801 New York, NY 10151 Crown Laboratories, Inc. c/o Hildred Capital Management, LLC 745 Fifth Avenue Suite 801 New York, NY 10151 Project Reba Amended and R |
|
| January 2, 2025 |
Skadden, Arps, Slate, Meagher & Flom llp ONE MANHATTAN WEST NEW YORK, NY 10001 TEL: (212) 735-3000 FAX: (212) 735-2000 www. |
|
| December 12, 2024 |
Exhibit (d)(8) LIMITED GUARANTEE This Limited Guarantee, dated as of August 11, 2024 (this “Limited Guarantee”), by Hildred Perennial Partners I, LP, Hildred Capital Co-Invest-REBA, LP, Hildred Equity Partners III, LP, Hildred Equity Partners III-A, LP, Hildred Equity Partners II, LP, Hildred Equity Associates II, LP, Hildred Equity Partners II-FR, LP and Hildred Equity Partners II-A, LP, each a Delaware limited partnership (each of the foregoing, a “Guarantor” and collectively, the “Guarantors”) is made in favor of Revance Therapeutics, Inc. |
|
| December 12, 2024 |
AMENDED AND RESTATED LIMITED GUARANTEE Execution Version Exhibit (d)(9) AMENDED AND RESTATED LIMITED GUARANTEE This Amended and Restated Limited Guarantee, dated as of December 7, 2024 (this “Limited Guarantee”), by Hildred Perennial Partners I, LP, Hildred Capital Co-Invest-REBA, LP, Hildred Equity Partners III, LP and Hildred Equity Partners III-A, LP, each a Delaware limited partnership (each of the foregoing, a “Guarantor” and collectively, the “Guarantors”) and solely for the purposes of Section 10, Hildred Equity Partners II, LP, Hildred Equity Associates II, LP, Hildred Equity Partners II-FR, LP and Hildred Equity Partners II-A, LP, each a Delaware limited partnership, is made in favor of Revance Therapeutics, Inc. |
|
| December 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Rule 14d-101) Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 Revance Therapeutics, Inc. (Name of Subject Company) Revance Therapeutics, Inc. (Name of Persons Filing Statement) Common Stock, par value $0.001 per share (Title of Class of Securities) 761330109 ( |
|
| December 12, 2024 |
AMENDMENT TO THE AMENDED AND RESTATED AGREEMENT AND PLAN OF MERGER Exhibit 2.1 AMENDMENT TO THE AMENDED AND RESTATED AGREEMENT AND PLAN OF MERGER This AMENDMENT TO THE AMENDED AND RESTATED AGREEMENT AND PLAN OF MERGER is made and entered into as of December 11, 2024 (this “Amendment”), by and among Crown Laboratories, Inc., a Delaware corporation (“Parent”), Reba Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Parent (“Merger Sub,” and tog |
|
| December 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO Tender Offer Statement under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 REVANCE THERAPEUTICS, INC. (Name of Subject Company (issuer)) REBA MERGER SUB, INC. (Offeror) a wholly-owned subsidiary of CROWN LABORATORIES, INC. (Parent of Offeror) CROWN HOLDINGS INTERCO LLC (Other) CROWN LABORATORI |
|
| December 12, 2024 |
AMENDMENT TO THE AMENDED AND RESTATED AGREEMENT AND PLAN OF MERGER Exhibit (d)(10) EXECUTION VERSION AMENDMENT TO THE AMENDED AND RESTATED AGREEMENT AND PLAN OF MERGER This AMENDMENT TO THE AMENDED AND RESTATED AGREEMENT AND PLAN OF MERGER is made and entered into as of December 11, 2024 (this “Amendment”), by and among Crown Laboratories, Inc. |
|
| December 12, 2024 |
Exhibit (a)(1)(E) This announcement is neither an offer to purchase nor a solicitation of an offer to sell Shares (as defined below). |
|
| December 12, 2024 |
Exhibit (a)(1)(D) Offer to Purchase All Outstanding Shares of Common Stock of REVANCE THERAPEUTICS, INC. |
|
| December 12, 2024 |
Execution Version Exhibit (d)(7) Hildred Perennial Partners I, LP Hildred Capital Co-Invest-REBA, LP Hildred Equity Partners III, LP Hildred Equity Partners III-A December 7, 2024 Crown Laboratories, Inc. |
|
| December 12, 2024 |
Exhibit (a)(1)(C) Offer to Purchase All Outstanding Shares of Common Stock of REVANCE THERAPEUTICS, INC. |
|
| December 12, 2024 |
Table of Contents Exhibit (a)(1)(A) Offer to Purchase All Outstanding Shares of Common Stock of REVANCE THERAPEUTICS, INC. |
|
| December 12, 2024 |
Exhibit (a)(5)(L) Crown Laboratories Commences Friendly Tender Offer for All Outstanding Common Shares of Revance Therapeutics at $3. |
|
| December 12, 2024 |
Exhibit 107 Calculation of Filing Fee Tables Schedule TO REVANCE THERAPEUTICS, INC. |
|
| December 12, 2024 |
Exhibit (d)(6) Hildred Perennial Partners I, LP Hildred Capital Co-Invest-REBA, LP Hildred Equity Partners III, LP Hildred Equity Partners III-A Hildred Equity Partners II, LP Hildred Equity Associates II, LP Hildred Equity Partners II-FR, LP Hildred Equity Partners II-A, LP August 11, 2024 Crown Laboratories, Inc. |
|
| December 12, 2024 |
MUTUAL NONDISCLOSURE AGREEMENT Exhibit (d)(5) MUTUAL NONDISCLOSURE AGREEMENT In connection with the consideration of a potential license, partnership or negotiated transaction (the “Transaction”) with Hildred Capital Management, LLC (herein, “Hildred Capital”) involving Crown Laboratories Holdings, Inc. |
|
| December 12, 2024 |
Exhibit (a)(1)(B) LETTER OF TRANSMITTAL to Tender Shares of Common Stock of REVANCE THERAPEUTICS, INC. |
|
| December 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 12, 2024 (December 11, 2024) Revance Therapeutics, Inc. (Exact name of registrant as specified in charter) Delaware 001-36297 77-0551645 (State or other jurisdiction of incor |
|
| December 9, 2024 |
Crown Laboratories and Revance Enter into Amended and Restated Merger Agreement Exhibit 99.1 Crown Laboratories and Revance Enter into Amended and Restated Merger Agreement Johnson City and Nashville, Tenn. – December 9, 2024 ― Crown Laboratories, Inc. (“Crown”), a privately held, global innovative leader in the skincare industry, and Revance Therapeutics, Inc. (“Revance”) (NASDAQ: RVNC), a biotechnology company aimed at setting the new standard in healthcare with innovative |
|
| December 9, 2024 |
Exhibit 99.2 Date: Monday, December 9th To: All Employees Dear Revance Family, Today, we announced that we agreed to revised deal terms with Crown Laboratories and have entered into an amended and restated merger agreement. Following consummation of the pending merger, we believe the combined organization will be one of the leading global aesthetics and skincare companies, encompassing one of the |
|
| December 9, 2024 |
Crown Laboratories and Revance Enter into Amended and Restated Merger Agreement Exhibit 99.1 Crown Laboratories and Revance Enter into Amended and Restated Merger Agreement Johnson City and Nashville, Tenn. – December 9, 2024 — Crown Laboratories, Inc. (“Crown”), a privately held, global innovative leader in the skincare industry, and Revance Therapeutics, Inc. (“Revance”) (NASDAQ: RVNC), a biotechnology company aimed at setting the new standard in healthcare with innovative |
|
| December 9, 2024 |
AMENDED AND RESTATED TENDER AND SUPPORT AGREEMENT Exhibit 10.1 Execution Version AMENDED AND RESTATED TENDER AND SUPPORT AGREEMENT This AMENDED AND RESTATED TENDER AND SUPPORT AGREEMENT (this “Agreement”), dated as of December 7, 2024, is entered into by and among Crown Laboratories, Inc., a Delaware corporation (“Parent”), Reba Merger Sub, Inc., a Delaware corporation and wholly-owned subsidiary of Parent (“Merger Sub”), and the stockholders of |
|
| December 9, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Rule 14d-101) Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 Revance Therapeutics, Inc. (Name of Subject Company) Revance Therapeutics, Inc. (Name of Persons Filing Statement) Common Stock, par value $0.001 per share (Title of Class of Securities) 761330109 ( |
|
| December 9, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 7, 2024 Revance Therapeutics, Inc. (Exact name of registrant as specified in charter) Delaware 001-36297 77-0551645 (State or other jurisdiction of incorporation) (Commission |
|
| December 9, 2024 |
Crown Laboratories and Revance Enter into Amended and Restated Merger Agreement Exhibit 99.1 Crown Laboratories and Revance Enter into Amended and Restated Merger Agreement Johnson City and Nashville, Tenn. – December 9, 2024 ― Crown Laboratories, Inc. (“Crown”), a privately held, global innovative leader in the skincare industry, and Revance Therapeutics, Inc. (“Revance”) (NASDAQ: RVNC), a biotechnology company aimed at setting the new standard in healthcare with innovative |
|
| December 9, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO Tender Offer Statement under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 REVANCE THERAPEUTICS, INC. (Name of Subject Company (issuer)) REBA MERGER SUB, INC. (Offeror) a wholly-owned subsidiary of CROWN LABORATORIES, INC. (Parent of Offeror) (Names of Filing Persons (identifying status as off |
|
| December 9, 2024 |
Talking points for Crown Aesthetics Team Exhibit 99.3 Talking points for Crown Aesthetics Team What should we communicate to HCPs when they ask: Why were Crown and Revance the best partners for this merger? What was the merger rationale? • Upon completion of the merger, we believe the combined company will be one of the leading global aesthetics and skincare companies, and encompass one of the most comprehensive portfolios of cutting-edg |
|
| December 9, 2024 |
Exhibit 2.1 Execution Version AMENDED AND RESTATED AGREEMENT AND PLAN OF MERGER by and among CROWN LABORATORIES, INC., REBA MERGER SUB, INC. and REVANCE THERAPEUTICS, INC. Dated as of December 7, 2024 TABLE OF CONTENTS Page ARTICLE I DEFINITIONS & INTERPRETATIONS 3 1.1 Certain Definitions 3 1.2 Additional Definitions 17 1.3 Certain Interpretations 20 Article II THE OFFER 22 2.1 The Offer 22 2.2 Co |
|
| December 9, 2024 |
Exhibit 99.2 LETTER TO EMPLOYEES TO: Crown Laboratories Employees FROM: Jeff Bedard, Founder and Chief Executive Officer; Nadeem Moiz, President, Chief Operating Officer and Chief Financial Officer DATE: December 9, 2024 RE: All Hands Company Update Hello Crown Team, We are excited to announce that we have reached a revised deal with Revance Therapeutics. This marks a significant step forward in t |
|
| December 5, 2024 |
TWELFTH WAIVER TO AGREEMENT AND PLAN OF MERGER Exhibit 99.1 TWELFTH WAIVER TO AGREEMENT AND PLAN OF MERGER This TWELFTH WAIVER TO AGREEMENT AND PLAN OF MERGER (this “Waiver”), dated December 5, 2024, is made by and among Crown Laboratories, Inc., a Delaware corporation (“Parent”), Reba Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent (“Merger Sub”), and Revance Therapeutics, Inc., a Delaware corporation (the “Co |
|
| December 5, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 5, 2024 Revance Therapeutics, Inc. (Exact name of registrant as specified in charter) Delaware 001-36297 77-0551645 (State or other jurisdiction of incorporation) (Commission |
|
| December 3, 2024 |
ELEVENTH WAIVER TO AGREEMENT AND PLAN OF MERGER Exhibit 99.1 ELEVENTH WAIVER TO AGREEMENT AND PLAN OF MERGER This ELEVENTH WAIVER TO AGREEMENT AND PLAN OF MERGER (this “Waiver”), dated December 3, 2024, is made by and among Crown Laboratories, Inc., a Delaware corporation (“Parent”), Reba Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent (“Merger Sub”), and Revance Therapeutics, Inc., a Delaware corporation (the “ |
|
| December 3, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 3, 2024 Revance Therapeutics, Inc. (Exact name of registrant as specified in charter) Delaware 001-36297 77-0551645 (State or other jurisdiction of incorporation) (Commission |
|
| November 29, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 29, 2024 Revance Therapeutics, Inc. (Exact name of registrant as specified in charter) Delaware 001-36297 77-0551645 (State or other jurisdiction of incorporation) (Commissio |
|
| November 29, 2024 |
TENTH WAIVER TO AGREEMENT AND PLAN OF MERGER Exhibit 99.1 TENTH WAIVER TO AGREEMENT AND PLAN OF MERGER This TENTH WAIVER TO AGREEMENT AND PLAN OF MERGER (this “Waiver”), dated November 29, 2024, is made by and among Crown Laboratories, Inc., a Delaware corporation (“Parent”), Reba Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent (“Merger Sub”), and Revance Therapeutics, Inc., a Delaware corporation (the “Compa |
|
| November 26, 2024 |
NINTH WAIVER TO AGREEMENT AND PLAN OF MERGER Exhibit 99.1 NINTH WAIVER TO AGREEMENT AND PLAN OF MERGER This NINTH WAIVER TO AGREEMENT AND PLAN OF MERGER (this “Waiver”), dated November 26, 2024, is made by and among Crown Laboratories, Inc., a Delaware corporation (“Parent”), Reba Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent (“Merger Sub”), and Revance Therapeutics, Inc., a Delaware corporation (the “Compa |
|
| November 26, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 26, 2024 Revance Therapeutics, Inc. (Exact name of registrant as specified in charter) Delaware 001-36297 77-0551645 (State or other jurisdiction of incorporation) (Commissio |
|
| November 19, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 19, 2024 Revance Therapeutics, Inc. (Exact name of registrant as specified in charter) Delaware 001-36297 77-0551645 (State or other jurisdiction of incorporation) (Commissio |
|
| November 19, 2024 |
EIGHTH WAIVER TO AGREEMENT AND PLAN OF MERGER Exhibit 99.1 EIGHTH WAIVER TO AGREEMENT AND PLAN OF MERGER This EIGHTH WAIVER TO AGREEMENT AND PLAN OF MERGER (this “Waiver”), dated November 19, 2024, is made by and among Crown Laboratories, Inc., a Delaware corporation (“Parent”), Reba Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent (“Merger Sub”), and Revance Therapeutics, Inc., a Delaware corporation (the “Com |
|
| November 12, 2024 |
SEVENTH WAIVER TO AGREEMENT AND PLAN OF MERGER Exhibit 99.1 SEVENTH WAIVER TO AGREEMENT AND PLAN OF MERGER This SEVENTH WAIVER TO AGREEMENT AND PLAN OF MERGER (this “Waiver”), dated November 12, 2024, is made by and among Crown Laboratories, Inc., a Delaware corporation (“Parent”), Reba Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent (“Merger Sub”), and Revance Therapeutics, Inc., a Delaware corporation (the “C |
|
| November 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 12, 2024 Revance Therapeutics, Inc. (Exact name of registrant as specified in charter) Delaware 001-36297 77-0551645 (State or other jurisdiction of incorporation) (Commissio |
|
| November 7, 2024 |
Fifth Amendment to the Exclusive Distribution Agreement dated January 10, 2020 dated July 29th, 2024 by and among Teoxane SA (the Supplier) Rue de Lyon 105, CH-1203 Geneva, Switzerland and Revance Therapeutics Inc. |
|
| November 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 7, 2024 Revance Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36297 77-0551645 (State or other jurisdiction of incorporation) (Commis |
|
| November 7, 2024 |
Fourth Amendment to the Exclusive Distribution Agreement dated January 10, 2020 dated June 13, 2024 by and among Teoxane SA (the Supplier) Rue de Lyon 105, CH-1203 Geneva, Switzerland and Revance Therapeutics Inc. |
|
| November 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001-36297 Revance T |
|
| November 7, 2024 |
Revance Reports Third Quarter 2024 Financial Results, Provides Corporate Update Exhibit 99.1 Revance Reports Third Quarter 2024 Financial Results, Provides Corporate Update –On August 11, 2024, Revance and Crown Laboratories, Inc. entered into a merger agreement. As a result of discussions between the Revance and Teoxane, Crown and Revance agreed to extend the deadline upon which the tender offer must commence to November 12, 2024. The tender offer has not yet commenced. –Rev |
|
| November 1, 2024 |
SIXTH WAIVER TO AGREEMENT AND PLAN OF MERGER Exhibit 99.1 SIXTH WAIVER TO AGREEMENT AND PLAN OF MERGER This SIXTH WAIVER TO AGREEMENT AND PLAN OF MERGER (this “Waiver”), dated November 1, 2024, is made by and among Crown Laboratories, Inc., a Delaware corporation (“Parent”), Reba Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent (“Merger Sub”), and Revance Therapeutics, Inc., a Delaware corporation (the “Compan |
|
| November 1, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 1, 2024 Revance Therapeutics, Inc. (Exact name of registrant as specified in charter) Delaware 001-36297 77-0551645 (State or other jurisdiction of incorporation) (Commission |
|
| October 28, 2024 |
, Revance Therapeutics, Inc. and Revance Australia Pty. Ltd. Exhibit 10.2 EXCLUSIVE DISTRIBUTION AGREEMENT This EXCLUSIVE DISTRIBUTION AGREEMENT (this “Agreement”), dated as of October 24, 2024 (the “Effective Date”), is entered into by and between Revance Therapeutics, Inc., a Delaware corporation with its principal place of business at 1222 Demonbreun St., 20th Floor, Nashville, TN 37203 and Revance Australia Pty. Ltd., an Australia proprietary company wi |
|
| October 28, 2024 |
FIFTH WAIVER TO AGREEMENT AND PLAN OF MERGER Exhibit 99.1 FIFTH WAIVER TO AGREEMENT AND PLAN OF MERGER This FIFTH WAIVER TO AGREEMENT AND PLAN OF MERGER (this “Waiver”), dated October 25, 2024, is made by and among Crown Laboratories, Inc., a Delaware corporation (“Parent”), Reba Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent (“Merger Sub”), and Revance Therapeutics, Inc., a Delaware corporation (the “Compan |
|
| October 28, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 24, 2024 Revance Therapeutics, Inc. (Exact name of registrant as specified in charter) Delaware 001-36297 77-0551645 (State or other jurisdiction of incorporation) (Commission |
|
| October 28, 2024 |
Sixth Amendment to Exclusive Distribution Agreement dated Exhibit 10.1 Sixth Amendment to the Exclusive Distribution Agreement dated January 10, 2020 dated October 24, 2024 by and among Teoxane SA (the Supplier) Rue de Lyon 105, CH-1203 Geneva, Switzerland and Revance Therapeutics Inc. (the Distributor) 1222 Demonbreun Street, Suite 2000, Nashville, Tennessee 37203 (the Supplier and the Distributor, together the Parties, and each a Party) Preamble A. On |
|
| October 23, 2024 |
RVNC / Revance Therapeutics, Inc. / GIC Private Ltd - SC 13G/A Passive Investment SC 13G/A 1 ef20037606sc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 5) * Revance Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 761330109 (CUSIP Number) September 30, 2024 (Date of the Event Which Requires Filing of this Sta |
|
| October 18, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 18, 2024 Revance Therapeutics, Inc. (Exact name of registrant as specified in charter) Delaware 001-36297 77-0551645 (State or other jurisdiction of incorporation) (Commission |
|
| October 18, 2024 |
FOURTH WAIVER TO AGREEMENT AND PLAN OF MERGER Exhibit 99.1 FOURTH WAIVER TO AGREEMENT AND PLAN OF MERGER This FOURTH WAIVER TO AGREEMENT AND PLAN OF MERGER (this “Waiver”), dated October 18, 2024, is made by and among Crown Laboratories, Inc., a Delaware corporation (“Parent”), Reba Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent (“Merger Sub”), and Revance Therapeutics, Inc., a Delaware corporation (the ”Comp |
|
| October 7, 2024 |
RVNC / Revance Therapeutics, Inc. / Capital World Investors - SEC SCHEDULE 13G Passive Investment SC 13G/A 1 SEC13GFiling.htm SEC SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 5 )* Revance Therapeutics, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 761330109 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropriat |
|
| October 4, 2024 |
THIRD WAIVER TO AGREEMENT AND PLAN OF MERGER Exhibit 99.1 THIRD WAIVER TO AGREEMENT AND PLAN OF MERGER This THIRD WAIVER TO AGREEMENT AND PLAN OF MERGER (this “Waiver”), dated October 3, 2024, is made by and among Crown Laboratories, Inc., a Delaware corporation (“Parent”), Reba Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent (“Merger Sub”), and Revance Therapeutics, Inc., a Delaware corporation (the “Company |
|
| October 4, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 3, 2024 Revance Therapeutics, Inc. (Exact name of registrant as specified in charter) Delaware 001-36297 77-0551645 (State or other jurisdiction of incorporation) (Commission |
|
| September 23, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 19, 2024 Revance Therapeutics, Inc. (Exact name of registrant as specified in charter) Delaware 001-36297 77-0551645 (State or other jurisdiction of incorporation) (Commissi |
|
| September 23, 2024 |
SECOND WAIVER TO AGREEMENT AND PLAN OF MERGER Exhibit 99.1 SECOND WAIVER TO AGREEMENT AND PLAN OF MERGER This SECOND WAIVER TO AGREEMENT AND PLAN OF MERGER (this “Waiver”), dated September 19, 2024, is made by and among Crown Laboratories, Inc., a Delaware corporation (“Parent”), Reba Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent (“Merger Sub”), and Revance Therapeutics, Inc., a Delaware corporation (the “Co |
|
| September 16, 2024 |
RVNC / Revance Therapeutics, Inc. / Beryl Capital Management LLC Passive Investment SC 13G 1 rvnc13g.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Revance Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 761330109 (CUSIP Number) September 5, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropria |
|
| September 9, 2024 |
RVNC / Revance Therapeutics, Inc. / Capital World Investors - SEC SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 4 )* Revance Therapeutics, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 761330109 (CUSIP Number) August 30, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which th |
|
| September 9, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 9, 2024 Revance Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36297 77-0551645 (State or other jurisdiction of incorporation) (Commi |
|
| September 5, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO Tender Offer Statement under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 REVANCE THERAPEUTICS, INC. (Name of Subject Company (issuer)) REBA MERGER SUB, INC. (Offeror) a wholly-owned subsidiary of CROWN LABORATORIES, INC. (Parent of Offeror) (Names of Filing Persons (identifying status as off |
|
| September 5, 2024 |
Exhibit 99.1 From: Mark Foley Date: September 5, 2024 Subject: CEO Business Update Revance Family, I hope everyone had a great holiday weekend and that you found time to relax with family and friends. It has been a few weeks since our merger announcement, so I wanted to take time out to provide an update on important work that has been underway. While it is still early on, these are important foun |
|
| September 5, 2024 |
Exhibit 99.1 TO: Crown Associates FROM: Jeff Bedard, Founder & Chief Executive Officer DATE: September 5, 2024 RE: Update on Merger Agreement Hi all, I hope you had a great holiday weekend and were able to find some time to relax with family and friends. As we close out the summer and head into fall, I would like to provide you with an update on some of the ways we’ve been working diligently on th |
|
| September 5, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Rule 14d-101) Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 Revance Therapeutics, Inc. (Name of Subject Company) Revance Therapeutics, Inc. (Name of Persons Filing Statement) Common Stock, par value $0.001 per share (Title of Class of Securities) 761330109 ( |
|
| August 28, 2024 |
WAIVER TO AGREEMENT AND PLAN OF MERGER Exhibit 99.1 WAIVER TO AGREEMENT AND PLAN OF MERGER This WAIVER TO AGREEMENT AND PLAN OF MERGER (this “Waiver”), dated August 27, 2024, is made by and among Crown Laboratories, Inc., a Delaware corporation (“Parent”), Reba Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent (“Merger Sub”), and Revance Therapeutics, Inc., a Delaware corporation (the “Company”), and waiv |
|
| August 28, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 27, 2024 Revance Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36297 77-0551645 (State or other jurisdiction of incorporation) (Commiss |
|
| August 12, 2024 |
Exhibit 99.1 Crown Laboratories and Revance Announce Entry Into Merger Agreement Combination provides opportunity to create a leading, innovative, high-growth aesthetics and skincare company Brings together two high-quality, complementary product lines Combined company’s flagship brands to include DAXXIFY® (toxin), the RHA® Collection (filler), SkinPen® (microneedling), PanOxyl® (acne), Blue Lizar |
|
| August 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO Tender Offer Statement under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 REVANCE THERAPEUTICS, INC. (Name of Subject Company (issuer)) REBA MERGER SUB, INC. (Offeror) a wholly-owned subsidiary of CROWN LABORATORIES, INC. (Parent of Offeror) (Names of Filing Persons (identifying status as off |
|
| August 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Rule 14d-101) Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 Revance Therapeutics, Inc. (Name of Subject Company) Revance Therapeutics, Inc. (Name of Persons Filing Statement) Common Stock, par value $0.001 per share (Title of Class of Securities) 761330109 ( |
|
| August 12, 2024 |
Exhibit 99.3 Employee FAQs These are designed to support senior leaders when prompted by employees with questions regarding the deal announcement Q. Who is Crown Laboratories? A. Crown Laboratories, Inc. (“Crown”), is a privately held, global innovative leader in the skincare industry dedicated to developing and providing a diverse portfolio of safe and effective scientific solutions for life-long |
|
| August 12, 2024 |
Exhibit 99.5 CROWN CEO LETTER TO SALESFORCE TO: Crown Salesforce Team FROM: Jeff Bedard, Founder and Chief Executive Officer DATE: August 12, 2024 RE: Exciting Development for Our Company & Customers Hi X, I am writing to share some exciting news about our company, as we have taken a significant step forward in our vision to become a fully integrated global skincare company. Today, we announced th |
|
| August 12, 2024 |
Salesforce FAQ’s Customer Facing Preparation Exhibit 99.7 Salesforce FAQ’s Customer Facing Preparation How will this change impact my practice or my patients? • There will be no immediate impact – it will be business as usual – and we will continue to operate as independent companies until the deal closes. • Upon completion of the deal, Crown expects to have one of the most comprehensive portfolios of skin health and aesthetic brands – so we |
|
| August 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 11, 2024 Revance Therapeutics, Inc. (Exact name of registrant as specified in charter) Delaware 001-36297 77-0551645 (State or other jurisdiction of incorporation) (Commission |
|
| August 12, 2024 |
Exhibit 99.2 All Employee CEO Memo I am writing to share an important milestone and some very exciting news about our company, as we have taken a significant step forward in the future growth and development of Revance. Today we announced that Revance has agreed to merge with Crown Laboratories, a global innovative leader in the skincare industry. For background, Crown was started in 2000 by Jeff |
|
| August 12, 2024 |
Exhibit 99.4 CROWN CEO LETTER TO SUPPLIERS TO: Crown Suppliers FROM: Jeff Bedard, Founder and Chief Executive Officer DATE: August 12, 2024 RE: Exciting Development for Our Company Hi X, I am writing to share some exciting news about our company, as we have taken a significant step forward in our vision to become a fully integrated global skincare company. Today, we announced that Crown has entere |
|
| August 12, 2024 |
Crown Laboratories and Revance Announce Entry Into Merger Agreement Exhibit 99.1 Crown Laboratories and Revance Announce Entry Into Merger Agreement Combination provides opportunity to create a leading, innovative, high-growth aesthetics and skincare company Brings together two high-quality, complementary product lines Combined company’s flagship brands to include DAXXIFY® (toxin), the RHA® Collection (filler), SkinPen® (microneedling), PanOxyl® (acne), Blue Lizar |
|
| August 12, 2024 |
Exhibit 99.2 KEY MESSAGES GENERAL MESSAGING (FOR EXTERNAL + INTERNAL AUDIENCES) Business Rationale • Crown Laboratories (“Crown”), a global innovative leader in the skincare industry, and Revance Therapeutics, Inc. (“Revance”) (NASDAQ: RVNC), an aesthetics company setting the new standard in healthcare with innovative aesthetic and therapeutic offerings that enhance patient outcomes and physician |
|
| August 12, 2024 |
Exhibit 99.6 CROWN CEO LETTER TO CUSTOMERS TO: Crown Customers & KOLs FROM: Jeff Bedard, Founder and Chief Executive Officer DATE: August 12, 2024 RE: Exciting Development for Our Company Hi X, I am writing to share some exciting news about our company, as we have taken a significant step forward in our vision to become a fully integrated global skincare company with safe and effective scientific |
|
| August 12, 2024 |
Exhibit 99.1 Crown Laboratories and Revance Announce Entry Into Merger Agreement Combination provides opportunity to create a leading, innovative, high-growth aesthetics and skincare company Brings together two high-quality, complementary product lines Combined company’s flagship brands to include DAXXIFY® (toxin), the RHA® Collection (filler), SkinPen® (microneedling), PanOxyl® (acne), Blue Lizar |
|
| August 12, 2024 |
Exhibit 99.3 CROWN CEO LETTER TO EMPLOYEES TO: Crown Laboratories Employees FROM: Jeff Bedard, Founder and Chief Executive Officer DATE: August 12, 2024 RE: Exciting Development for Our Company Crown Family, I am writing to share some very exciting news about our company, as we have taken a significant step forward in our vision to become a leading global aesthetics and skincare company. Today we |
|
| August 12, 2024 |
Exhibit 2.1 AGREEMENT AND PLAN OF MERGER by and among Crown Laboratories, Inc. Reba Merger Sub, Inc. and Revance Therapeutics, Inc. August 11, 2024 TABLE OF CONTENTS Page ARTICLE I DEFINITIONS & INTERPRETATIONS 2 1.1 Certain Definitions 2 1.2 Additional Definitions 14 1.3 Certain Interpretations 16 Article II THE OFFER 18 2.1 The Offer 18 2.2 Company Action 21 Article III THE MERGER 22 3.1 The Mer |
|
| August 9, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 8, 2024 Revance Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36297 77-0551645 (State or other jurisdiction of incorporation) (Commissi |
|
| August 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 8, 2024 Revance Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36297 77-0551645 (State or other jurisdiction of incorporation) (Commissi |
|
| August 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001-36297 Revance Therap |
|
| August 8, 2024 |
Revance Reports Second Quarter 2024 Financial Results, Provides Corporate Update Exhibit 99.1 Revance Reports Second Quarter 2024 Financial Results, Provides Corporate Update –Q2 total DAXXIFY® and RHA® (by Teoxane SA) product revenue of $65.3 million, a YoY increase of 20%. –Q2 DAXXIFY net revenue of $28.7 million, a YoY increase of 27%. –Q2 DAXXIFY aesthetic units sold increased 65% YoY and 15% QoQ; over 3,700 ordering accounts reached. –Q2 RHA Collection net revenue of $36. |
|
| May 9, 2024 |
ween Revance Therapeutics, Inc. and Erica Jordan Exhibit 10.4 1222 Demonbreun Street, 20th Floor Nashville, TN 37203 www.Revance.com February 21, 2023 Erica Jordan Via Electronic Delivery Dear Erica, We are pleased to offer you the position of Senior Vice President, Strategy at Revance (the “Company”), reporting directly to Dustin Sjuts, President. We look forward to the significant contributions you will make at Revance as we continue to grow a |
|
| May 9, 2024 |
Revance Reports First Quarter 2024 Financial Results, Provides Corporate Update Exhibit 99.1 Revance Reports First Quarter 2024 Financial Results, Provides Corporate Update –Total net product revenue (DAXXIFY® and RHA® Collection) of $51.7 million, a YoY increase of 13%. –DAXXIFY® net revenue of $22.1 million, after a reduction of $2.0 million related to a consumer coupon program. –Toxin market share increased from 3.0% in Q4’23 to 3.7% in Q1’24. –Aesthetic units sold increas |
|
| May 9, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 9, 2024 Revance Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36297 77-0551645 (State or other jurisdiction of incorporation) (Commission |
|
| May 9, 2024 |
ffer Letter dated September 29, 2022 by and between Revance Therapeutics, Inc. and David Hollander Exhibit 10.3 1222 Demonbreun Street, 20th Floor Nashville, TN 37203 www.Revance.com September 29, 2022 David A. Hollander, MD [email protected] via Electronic Delivery Dear David, Subject to approval by Compensation Committee of the Board, we are pleased to offer you the position of Chief Medical Officer at Revance (the “Company”), reporting directly to Dustin Sjuts, President. We loo |
|
| May 9, 2024 |
Revance Therapeutics, Inc. Amended and Restated Non-Employee Director Compensation Policy Exhibit 10.6 Revance Therapeutics, Inc. Amended and Restated Non-Employee Director Compensation Policy Each member of the Board of Directors (the “Board”) who is not also serving as an employee of Revance Therapeutics, Inc. (the “Company”) or any of its subsidiaries (each such member, an “Eligible Director”) will receive the compensation described in this Amended and Restated Non-Employee Director |
|
| May 9, 2024 |
Exhibit 99.2 Revance Expands into the U.S. Therapeutics Market with the Launch of DAXXIFY® for the Treatment of Cervical Dystonia –DAXXIFY® for the treatment of cervical dystonia is the first and only peptide-formulated, long-lasting neurotoxin that offers the potential to improve duration of symptom control1 –Revance has received a Permanent J-Code and has already secured coverage for 78% of comm |
|
| May 9, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001-36297 Revance Thera |
|
| May 3, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 1, 2024 Revance Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36297 77-0551645 (State or other jurisdiction of incorporation) (Commission |
|
| April 9, 2024 |
Schedule 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 10)* Revance Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 761330109 (CUSIP Number) March 29, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to |
|
| March 21, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ý Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ¨ Defin |
|
| March 21, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ý Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ý Defin |
|
| March 5, 2024 |
16,000,000 Shares Common Stock Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-275548 PROSPECTUS SUPPLEMENT (To Prospectus dated November 14, 2023) 16,000,000 Shares Common Stock We are offering 16,000,000 shares of our common stock, par value $0.001 per share. Our common stock is listed on The Nasdaq Global Market under the symbol “RVNC.” On March 4, 2024, the last reported sale price of our common stoc |
|
| March 5, 2024 |
Exhibit 107 Calculation of Filing Fee Tables 424(b)(5) (Form Type) Revance Therapeutics, Inc. |
|
| March 5, 2024 |
Underwriting Agreement, dated March 4, 2024, by and between the Company and the Underwriter Exhibit 1.1 Revance Therapeutics, Inc. Common Stock, par value $0.001 per share Underwriting Agreement March 4, 2024 BARCLAYS CAPITAL INC. As representative (the “Representative”) of the several Underwriters named in Schedule I hereto c/o Barclays Capital Inc. 745 Seventh Avenue New York, NY 10019 Ladies and Gentlemen: Revance Therapeutics, Inc., a Delaware corporation (the “Company”), proposes, s |
|
| March 5, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 4, 2024 Revance Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36297 77-0551645 (State or other jurisdiction of incorporation) (Commissio |
|
| March 4, 2024 |
SUBJECT TO COMPLETION, DATED MARCH 4, 2024 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-275548 The information in this preliminary prospectus supplement is not complete and may be changed. A registration statement relating to these securities has been filed with the Securities and Exchange Commission and is effective. This preliminary prospectus supplement and the accompanying prospectus are not an offer to sell |
|
| February 29, 2024 |
As filed with the Securities and Exchange Commission on February 28, 2024 As filed with the Securities and Exchange Commission on February 28, 2024 Registration No. |
|
| February 29, 2024 |
Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) Revance Therapeutics, Inc. |
|
| February 28, 2024 |
List of Subsidiaries of the Registrant Exhibit 21.1 REVANCE THERAPEUTICS, INC. LIST OF SUBSIDIARIES 1.Hint, Inc. (d/b/a HintMD), incorporated in Delaware. |
|
| February 28, 2024 |
, 2024, by and between Revance Therapeutics, Inc. and Dustin Sjuts Exhibit 10.2 February 23, 2024 (the “Execution Date”) Electronic Mail Dustin S. Sjuts Revance Therapeutics, Inc. Re: Separation Agreement Dear Dustin: This letter sets forth the substance of the mutual separation agreement (the “Agreement”) that Revance Therapeutics, Inc. (the “Company”) is offering to you to aid in your employment transition. 1.SEPARATION DATE. Your last day of work as the Compan |
|
| February 28, 2024 |
Revance Therapeutics, Inc. Incentive Compensation Recoupment Policy Exhibit 97.1 Revance Therapeutics, Inc. Incentive Compensation Recoupment Policy 1.Introduction The Compensation Committee (the “Compensation Committee”) of the Board of Directors (the “Board”) of Revance Therapeutics, Inc., a Delaware corporation (the “Company”), has determined that it is in the best interests of the Company and its stockholders to adopt this Incentive Compensation Recoupment Pol |
|
| February 28, 2024 |
Revance Therapeutics, Inc. 202 Exhibit 10.32 REVANCE THERAPEUTICS, INC. 2024 MANAGEMENT BONUS PROGRAM On February 7, 2024, upon recommendation of the Compensation Committee (the “Committee”) of the Board of Directors (the “Board”) of Revance Therapeutics, Inc. (the “Company”), the Board approved the Company’s 2024 corporate objectives, weighted for purposes of determining bonuses, if any, for the Company’s executive officers wi |
|
| February 28, 2024 |
Revance Reports Fourth Quarter and Full Year 2023 Financial Results, Provides Corporate Update Exhibit 99.1 Revance Reports Fourth Quarter and Full Year 2023 Financial Results, Provides Corporate Update –Q4 and full year 2023 product revenue (DAXXIFY® and RHA® Collection) of $58.5 million and $212.7 million, representing approximately 28% and 80% YoY growth, respectively. –Q4 DAXXIFY volume up 22% over Q3 2023, with over two-thirds of Q4 revenue attributable to reordering accounts. –2024 pr |
|
| February 28, 2024 |
Exhibit 4.4 DESCRIPTION OF REVANCE THERAPEUTICS, INC. SECURITIES The following is a description of the common stock, $0.001 par value (the “Common Stock”), of Revance Therapeutics, Inc. (“we” or the “Company”), which is the only security of the Company registered pursuant to Section 12 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). General Our Amended and Restated Certifi |
|
| February 28, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001-36297 Revance Therapeuti |
|
| February 28, 2024 |
Exhibit 10.1 AMENDMENT NO. 2 TO THE TECHNOLOGY TRANSFER, VALIDATION AND COMMERCIAL FILL/FINISH SERVICES AGREEMENT THIS AMENDMENT NO. 2 (this “Amendment”) is made and entered into as of February 23, 2024 (the “Amendment Effective Date”), by and between Revance Therapeutics, Inc., (“Client”), and Ajinomoto Althea, Inc., dba Ajinomoto Bio-Pharma Services, a California (formerly Delaware) corporation |
|
| February 28, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 23, 2024 Revance Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36297 77-0551645 (State or other jurisdiction of incorporation) (Commi |
|
| February 14, 2024 |
RVNC / Revance Therapeutics, Inc. / Palo Alto Investors LP Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (AMENDMENT NO. 3)* Revance Therapeutics, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 761330109 (CUSIP Number) December 31, 2023 (Date of Event which Re |
|
| February 14, 2024 |
RVNC / Revance Therapeutics, Inc. / Antara Capital LP Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G (Amendment No. 1) (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) Revance Therapeutics, Inc. (Name of Issuer) Common Stock, $.001 par value (Title of Class of Securities) 761330109 (CUSIP Number) December 3 |
|
| February 13, 2024 |
Amended and Restated Executive Severance Benefit Plan REVANCE THERAPEUTICS, INC. EXECUTIVE SEVERANCE BENEFIT PLAN Amended and Restated Effective February 7, 2024 1. INTRODUCTION. This Revance Therapeutics, Inc. Executive Severance Benefit Plan (the “Plan”) is established by Revance Therapeutics, Inc. (the “Company”). The Plan was originally adopted by the Board on December 17, 2013; became effective without further action on the IPO Date (as defined |
|
| February 13, 2024 |
RVNC / Revance Therapeutics, Inc. / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SC 13G/A 1 tv01818-revancetherapeuticsi.htm SCHEDULE 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 2)* Name of issuer: Revance Therapeutics Inc Title of Class of Securities: Common Stock CUSIP Number: 761330109 Date of Event Which Requires Filing of this Statement: December 29, 2023 Check the appropriate box t |
|
| February 13, 2024 |
RVNC / Revance Therapeutics, Inc. / Polar Capital Holdings Plc Passive Investment SC 13G/A 1 polar-rvnc123123a1.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* Revance Therapeutics, Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 761330109 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Check |
|
| February 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 7, 2024 Revance Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36297 77-0551645 (State or other jurisdiction of incorporation) (Commis |
|
| February 9, 2024 |
RVNC / Revance Therapeutics, Inc. / Capital World Investors - SEC SCHEDULE 13G Passive Investment SC 13G/A 1 SEC13GFiling.htm SEC SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3 )* Revance Therapeutics, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 761330109 (CUSIP Number) December 29, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate |
|
| February 9, 2024 |
RVNC / Revance Therapeutics, Inc. / GIC Private Ltd - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 4) * Revance Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 761330109 (CUSIP Number) December 31, 2023 (Date of the Event Which Requires Filing of this Statement) Check the appropriate box to desig |
|
| February 6, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 31, 2024 Revance Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36297 77-0551645 (State or other jurisdiction of incorporation) (Commis |
|
| February 6, 2024 |
RVNC / Revance Therapeutics, Inc. / FRANKLIN RESOURCES INC Passive Investment SC 13G 1 reva23in.htm CUSIP NO. 761330109 13G Page 1 of 14 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Revance Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 761330109 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing |
|
| January 25, 2024 |
SC 13G/A 1 RevanceTherapeuticsInc.h.htm FILING REVANCE THERAPEUTICS, INC. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 09)* Revance Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 761330109 (CUSIP Number) December 29, 2023 (Date of Event Which |
|
| January 25, 2024 |
Schedule 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 09)* Revance Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 761330109 (CUSIP Number) December 29, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box |
|
| January 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 8, 2024 Revance Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36297 77-0551645 (State or other jurisdiction of incorporation) (Commiss |
|
| January 8, 2024 |
Exhibit 99.1 Revance Provides Corporate Update, Preliminary Fourth Quarter and Full Year 2023 Financial Results, and Financial Outlook –Q4 DAXXIFY® volume sold up 22% over Q3, reflecting positive feedback on the product’s performance profile and the new pricing strategy. –Preliminary unaudited Q4 and full year 2023 product revenue (DAXXIFY and RHA® Collection) of between $58 million and $59 millio |
|
| December 15, 2023 |
AMENDED AND RESTATED BYLAWS OF REVANCE THERAPEUTICS, INC. (A DELAWARE CORPORATION) (Approved and Adopted December 12, 2023) TABLE OF CONTENTS ARTICLE I OFFICES 1 Section 1. Registered Office 1 Section 2. Other Offices 1 ARTICLE II CORPORATE SEAL 1 Section 3. Corporate Seal 1 ARTICLE III STOCKHOLDERS’ MEETINGS 1 Section 4. Place Of Meetings 1 Section 5. Annual Meetings. 1 Section 6. Special Meeting |
|
| December 15, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 12, 2023 Revance Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36297 77-0551645 (State or other jurisdiction of incorporation) (Commi |
|
| November 14, 2023 |
As filed with the Securities and Exchange Commission on November 14, 2023 S-3ASR Table of Contents As filed with the Securities and Exchange Commission on November 14, 2023 Registration No. |
|
| November 14, 2023 |
Form of Preferred Stock Warrant Agreement and Warrant Certificate. EX-4.7 Exhibit 4.7 REVANCE THERAPEUTICS, INC. AND , AS WARRANT AGENT FORM OF PREFERRED STOCK WARRANT AGREEMENT DATED AS OF REVANCE THERAPEUTICS, INC. FORM OF PREFERRED STOCK WARRANT AGREEMENT THIS PREFERRED STOCK WARRANT AGREEMENT (this “Agreement”), dated as of [•], between REVANCE THERAPEUTICS, INC., a Delaware corporation (the “Company”), and [•], a [corporation] [national banking association] |
|
| November 14, 2023 |
EX-FILING FEES Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Revance Therapeutics, Inc. |
|
| November 14, 2023 |
Form of Common Stock Warrant Agreement and Warrant Certificate. EX-4.6 Exhibit 4.6 REVANCE THERAPEUTICS, INC. AND , AS WARRANT AGENT FORM OF COMMON STOCK WARRANT AGREEMENT DATED AS OF REVANCE THERAPEUTICS, INC. FORM OF COMMON STOCK WARRANT AGREEMENT THIS COMMON STOCK WARRANT AGREEMENT (this “Agreement”), dated as of [•], between REVANCE THERAPEUTICS, INC., a Delaware corporation (the “Company”), and [•], a [corporation] [national banking association] organized |
|
| November 14, 2023 |
Form of Debt Securities Warrant Agreement and Warrant Certificate. EX-4.8 Exhibit 4.8 REVANCE THERAPEUTICS, INC. AND , AS WARRANT AGENT FORM OF DEBT SECURITIES WARRANT AGREEMENT DATED AS OF REVANCE THERAPEUTICS, INC. FORM OF DEBT SECURITIES WARRANT AGREEMENT THIS DEBT SECURITIES WARRANT AGREEMENT (this “Agreement”), dated as of [•], between REVANCE THERAPEUTICS, INC., a Delaware corporation (the “Company”), and [•], a [corporation] [national banking association] |
|
| November 8, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001-36297 Revance T |
|
| November 8, 2023 |
CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. |
|
| November 8, 2023 |
Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 8, 2023 Revance Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36297 77-0551645 (State or other jurisdiction of incorporation) (Commis |
|
| November 8, 2023 |
Revance Reports Third Quarter 2023 Financial Results, Provides Corporate Update Exhibit 99.1 Revance Reports Third Quarter 2023 Financial Results, Provides Corporate Update –Q3 total product revenue of $54.1 million, a YoY increase of 107.5%. –Q3 DAXXIFY® revenue of $22.0 million, and first full year revenue post approval of $71.0 million. –Q3 RHA® Collection revenue of $32.1 million, a YoY increase of 23.2%. –In August, DAXXIFY was approved by the FDA for the treatment of ce |
|
| October 24, 2023 |
RVNC / Revance Therapeutics Inc / Teoxane SA - SC 13D/A Activist Investment SC 13D/A 1 ef20013034sc13da.htm SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 1)* Revance Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 761330109 (CUSIP Number) Patrice Calvayrac Chief Financial Officer Teoxane SA Rue de Lyon 105 CH |
|
| September 19, 2023 |
Revance Provides Corporate Update at Investor Day EX-99.1 Exhibit 99.1 Revance Provides Corporate Update at Investor Day NASHVILLE, Tenn. – (BUSINESS WIRE) – September 19, 2023—Revance Therapeutics, Inc. (Nasdaq: RVNC) announced that the company is hosting its Investor Day today, September 19, 2023, from 9:30am ET to 12:00pm ET. The Investor Day will include management presentations on Revance’s vision and strategy, Revance Aesthetics overview an |
|
| September 19, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 17, 2023 Revance Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36297 77-0551645 (State or other jurisdiction of incorporation) (Comm |
|
| September 19, 2023 |
INVESTOR DAY 2023 WELCOME MARK J. FOLEY – CHIEF EXECUTIVE OFFICER Intended for investor audience Exhibit 99.2 INVESTOR DAY 2023 The presentations today contain information about Revance’s business for stockholders, potential investors, and financial analysts. The content shared is intended for this audience only. INVESTOR DAY 2023 WELCOME MARK J. FOLEY – CHIEF EXECUTIVE OFFICER Intended for investor audience INVESTOR DAY 2023 PR O GR A M REVANCE AESTHETICS DAXXIFY® KOL PANEL B R E AK REVANCE |
|
| September 1, 2023 |
RVNC / Revance Therapeutics Inc / Teoxane SA - SC 13D Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. )* Revance Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 761330109 (CUSIP Number) Patrice Calvayrac Chief Financial Officer Teoxane SA Rue de Lyon 105 CH 1203 Geneva, Switzerland +41 22 344 96 36 |
|
| August 31, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 30, 2023 Revance Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36297 77-0551645 (State or other jurisdiction of incorporation) (Commiss |
|
| August 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 11, 2023 Revance Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36297 77-0551645 (State or other jurisdiction of incorporation) (Commiss |
|
| August 8, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001-36297 Revance Therap |
|
| August 8, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 8, 2023 Revance Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36297 77-0551645 (State or other jurisdiction of incorporation) (Commissi |
|
| August 8, 2023 |
Revance Reports Second Quarter 2023 Financial Results, Provides Corporate Update Exhibit 99.1 Revance Reports Second Quarter 2023 Financial Results, Provides Corporate Update –Q2 total revenue of $58.1 million, a YoY increase of 104.9%. –Q2 RHA® Collection revenue of $31.8 million, a YoY increase of 24.7%. –Q2 DAXXIFY® revenue of $22.6 million, a QoQ increase of 47.1%. –Bolstered financial position with $100 million net proceeds from ATM program and $50 million in notes availa |
|
| May 9, 2023 |
by and between Revance Therapeutics, Inc. and THIRD AMENDMENT TO LEASE THIS THIRD AMENDMENT TO LEASE (the “Amendment”) is made effective as of the last date of execution on the signature page hereto (the “Effective Date”), by and between 1222 DEMONBREUN, LP, a Texas limited partnership (“Landlord”), and REVANCE THERAPEUTICS, INC. |
|
| May 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 9, 2023 Revance Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36297 77-0551645 (State or other jurisdiction of incorporation) (Commission |
|
| May 9, 2023 |
Dustin Sjuts President [*] March 22, 2023 By Email & Federal Express Ning Yuan [*] Re: Second Letter Amendment to the License Agreement Dear Ning, As you are aware, Revance Therapeutics, Inc. |
|
| May 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001-36297 Revance Thera |
|
| May 9, 2023 |
EXECUTION COPY LICENSE AND SERVICE AGREEMENT This License and Service Agreement (together with any Attachments hereto, the "Agreement") is entered into as of February 8, 2007 (the "Effective Date"), by and between Revance Therapeutics, Inc. |
|
| May 9, 2023 |
Revance Reports First Quarter 2023 Financial Results, Provides Corporate Update Exhibit 99.1 Revance Reports First Quarter 2023 Financial Results, Provides Corporate Update –Q1 total revenue of $49.3 million, a YoY increase of 95.3%. –Q1 RHA® Collection revenue of $30.3 million, a YOY increase of 45.3%. –Q1 DAXXIFY® revenue of $15.4 million, driven by PrevU and March launch. –FDA approves Ajinomoto Biopharma Services, Revance’s contract manufacturer for DAXXIFY®. –Fosun Pharm |
|
| May 9, 2023 |
FIRST ADDENDUM TO LICENSE AND SERVICE AGREEMENT THIS FIRST ADDENDUM ("First ·Addendum"), is made and entered into, effective as of April 21, 2009 ("First Addendum Date"), by and between Revance Therapeutics, Inc. |
|
| May 8, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 3, 2023 Revance Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36297 77-0551645 (State or other jurisdiction of incorporation) (Commission |
|
| April 19, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 19, 2023 Revance Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36297 77-0551645 (State or other jurisdiction of incorporation) (Commissi |
|
| March 31, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ý Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ¨ Defin |
|
| March 23, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ý Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ¨ Defin |
|
| March 23, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ý Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ý Defin |
|
| February 28, 2023 |
Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) Revance Therapeutics, Inc. |
|
| February 28, 2023 |
Revance Reports Fourth Quarter and Full Year 2022 Financial Results, Provides Corporate Update Exhibit 99.1 Revance Reports Fourth Quarter and Full Year 2022 Financial Results, Provides Corporate Update –Q4 and full year 2022 total revenue of $49.9 million and $132.6 million, a YoY increase of 92% and 70%, respectively. –Q4 and full year 2022 RHA® Collection revenue of $34.8 million and $107.2 million, a YoY increase of 46% and 51%, respectively. –DAXXIFY® Q4 PrevU revenue of $11.0 million, |
|
| February 28, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 22, 2023 Revance Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36297 77-0551645 (State or other jurisdiction of incorporation) (Commi |
|
| February 28, 2023 |
Exhibit 99.2 Revance Adds Experienced Pharmaceutical Executive to Board of Directors with Appointment of Dr. Vlad Coric, M.D., as Independent Director –Dr. Coric currently serves as the Chairman and Chief Executive Officer of Biohaven (BHVN) - NASHVILLE, Tenn.,-(BUSINESS WIRE)— February 28, 2023 - Revance Therapeutics, Inc. (RVNC, www.revance.com), announced today the appointment of Dr. Vlad Coric |
|
| February 28, 2023 |
Revance Therapeutics, Inc. 202 Exhibit 10.31 REVANCE THERAPEUTICS, INC. 2023 MANAGEMENT BONUS PROGRAM On February 1, 2023, the Compensation Committee of the Board of Directors of Revance Therapeutics, Inc. (the “Company”) approved the Company’s 2023 corporate objectives, weighted for purposes of determining bonuses, if any, for the Company’s executive officers with respect to 2023 performance (the “2023 Bonus Program”). The 202 |
|
| February 28, 2023 |
Exhibit 10.46 Third Amendment to the Exclusive Distribution Agreement dated January 10, 2020 dated December 16, 2022 by and among Teoxane SA (the Supplier) Rue de Lyon 105, CH-1203 Geneva, Switzerland and Revance Therapeutics Inc. (the Distributor) 7555 Gateway Boulevard Newark, California, USA (the Supplier and the Distributor, together the Parties, and each a Party) CERTAIN CONFIDENTIAL CERTAIN |
|
| February 28, 2023 |
Exhibit 99.2 Mandatory Sell to Cover Form Revance Therapeutics, Inc. Restricted Stock Unit Grant Notice (2014 Equity Incentive Plan) Revance Therapeutics, Inc. (the “Company”), pursuant to Section 6(b) of the Company’s 2014 Equity Incentive Plan (the “Plan”), hereby awards to Participant a Restricted Stock Unit Award for the number of shares of the Company’s Common Stock (“Restricted Stock Units”) |
|
| February 28, 2023 |
Exhibit 4.4 DESCRIPTION OF REVANCE THERAPEUTICS, INC. COMMON STOCK The following is a description of the common stock, $0.001 par value (the “Common Stock”), of Revance Therapeutics, Inc. (“we” or the “Company”), which is the only security of the Company registered pursuant to Section 12 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). General Our Amended and Restated Certi |
|
| February 28, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001-36297 Revance Therapeuti |
|
| February 28, 2023 |
Sell to Cover RSU Grant Package Revance Therapeutics, Inc. Restricted Stock Unit Grant Notice (2014 Inducement Plan) Revance Therapeutics, Inc. (the “Company”), pursuant to Section 6(b) of the Company’s 2014 Inducement Plan (the “Plan”), hereby awards to Participant, as an inducement material to Participant’s entering into employment with the Company, a Restricted Stock Unit Award for the number o |
|
| February 28, 2023 |
As filed with the Securities and Exchange Commission on February 28, 2023 As filed with the Securities and Exchange Commission on February 28, 2023 Registration No. |
|
| February 14, 2023 |
RVNC / Revance Therapeutics Inc / Antara Capital LP - SC 13G Passive Investment SC 13G 1 d431111dsc13g.htm SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G (Amendment No. ) (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) Revance Therapeutics, Inc. (Name of Issuer) Common Stock, $.001 par value (Title of Class of Securities) 76 |
|
| February 14, 2023 |
RVNC / Revance Therapeutics Inc / Polar Capital Holdings Plc Passive Investment SC 13G 1 polar-rvnc123122.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Revance Therapeutics, Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 761330109 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Statement) Check the ap |
|
| February 14, 2023 |
EX-99.1 2 d431111dex991.htm EX-99.1 Exhibit 99.1 JOINT FILING AGREEMENT Pursuant to and in accordance with the Securities Exchange Act of 1934, as amended, and the rules and regulations thereunder (the “Exchange Act”) the undersigned hereby agree to the joint filing of Antara Capital LP, Antara Capital GP LLC and Himanshu Gulati, on behalf of each of them of any filing required by such party under |
|
| February 13, 2023 |
RVNC / Revance Therapeutics Inc / Capital World Investors - SEC SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2 )* Revance Therapeutics, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 761330109 (CUSIP Number) December 30, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which |
|
| February 9, 2023 |
RVNC / Revance Therapeutics Inc / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SC 13G/A 1 tv01792-revancetherapeuticsi.htm SCHEDULE 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 1)* Name of issuer: Revance Therapeutics Inc. Title of Class of Securities: Common Stock CUSIP Number: 761330109 Date of Event Which Requires Filing of this Statement: December 30, 2022 Check the appropriate box |
|
| February 9, 2023 |
RVNC / Revance Therapeutics Inc / GIC Private Ltd - SC 13G/A Passive Investment SC 13G/A 1 brhc10047710sc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3) * Revance Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 761330109 (CUSIP Number) December 31, 2022 (Date of the Event Which Requires Filing of this St |
|
| February 3, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 31, 2023 Revance Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36297 77-0551645 (State or other jurisdiction of incorporation) (Commis |
|
| January 27, 2023 |
Schedule 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 08)* Revance Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 761330109 (CUSIP Number) December 30, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box |
|
| January 18, 2023 |
Entry into a Material Definitive Agreement UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 13, 2023 Revance Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36297 77-0551645 (State or other jurisdiction of incorporation) (Commis |
|
| January 9, 2023 |
Exhibit 99.1 Revance Provides an Update on DAXXIFY® Commercial Launch and Preliminary Fourth Quarter and Full Year 2022 Financial Results •DAXXIFY® PrevU program off to strong start with ~400 select practice partners and thousands of patients treated, generating positive feedback and strong, early uptake •Preliminary unaudited Q4 DAXXIFY® revenue from PrevU of between $10.5 million and $11.5 milli |
|
| January 9, 2023 |
Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 6, 2023 Revance Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36297 77-0551645 (State or other jurisdiction of incorporation) (Commiss |
|
| December 9, 2022 |
RVNC / Revance Therapeutics Inc / Capital World Investors - SEC SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1 )* Revance Therapeutics, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 761330109 (CUSIP Number) November 30, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which |
|
| November 8, 2022 |
Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 8, 2022 Revance Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36297 77-0551645 (State or other jurisdiction of incorporation) (Commis |
|
| November 8, 2022 |
Exhibit 10.1 Second Amendment to the Exclusive Distribution Agreement dated January 10, 2020 dated November 18, 2020 by and among Teoxane SA (the Supplier) Rue de Lyon 105, CH-1203 Geneva, Switzerland and Revance Therapeutics Inc. (the Distributor) 7555 Gateway Boulevard Newark, California, USA (the Supplier and the Distributor, together the Parties, and each a Party) Preamble A.On January 10, 202 |
|
| November 8, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001-36297 Revance T |
|
| November 8, 2022 |
Revance Reports Third Quarter 2022 Financial Results, Provides Corporate Update Exhibit 99.1 Revance Reports Third Quarter 2022 Financial Results, Provides Corporate Update ?Received FDA approval for DAXXIFY? (DaxibotulinumtoxinA-lanm) for injection for the treatment of glabellar lines ?Q3 total revenue of $29.0 million, a YoY increase of 47% with RHA? Collection revenue of $26.1 million, a YoY increase of 43% ?Aesthetic accounts across products and services totaled over 4,50 |
|
| October 20, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 20, 2022 Revance Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36297 77-0551645 (State or other jurisdiction of incorporation) (Commis |
|
| September 14, 2022 |
8,000,000 Shares Common Stock $25.00 per share Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-250998 PROSPECTUS SUPPLEMENT (To Prospectus dated November 27, 2020) 8,000,000 Shares Common Stock $25.00 per share We are offering 8,000,000 shares of our common stock. Our common stock is listed on The Nasdaq Global Market under the symbol ?RVNC.? On September 12, 2022, the last reported sale price of our common stock on The |
|
| September 14, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 12, 2022 Revance Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36297 77-0551645 (State or other jurisdiction of incorporation) (Comm |
|
| September 14, 2022 |
Underwriting Agreement, dated September 12, 2022, by and among the Company and the Underwriters EX-1.1 2 d404755dex11.htm EX-1.1 Exhibit 1.1 EXECUTION VERSION Revance Therapeutics, Inc. Common Stock, par value $0.001 per share Underwriting Agreement September 12, 2022 Goldman Sachs & Co. LLC Cowen and Company, LLC Guggenheim Securities, LLC As representatives (the “Representatives”) of the several Underwriters named in Schedule I hereto c/o Goldman Sachs & Co. LLC 200 West Street New York, N |
|
| September 14, 2022 |
Exhibit 107 Calculation of Filing Fee Tables 424(b)(5) (Form Type) Revance Therapeutics, Inc. |
|
| September 12, 2022 |
Subject to Completion, Dated September 12, 2022 424B5 1 d359293d424b5.htm 424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-250998 The information in this preliminary prospectus supplement is not complete and may be changed. A registration statement relating to these securities has been filed with the Securities and Exchange Commission and is effective. This preliminary prospectus supplement and the accompanying pros |
|
| September 8, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 8, 2022 Revance Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36297 77-0551645 (State or other jurisdiction of incorporation) (Commi |
|
| August 9, 2022 |
Regulation FD Disclosure, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 9, 2022 Revance Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36297 77-0551645 (State or other jurisdiction of incorporation) (Commissi |
|
| August 9, 2022 |
Revance Reports Second Quarter 2022 Financial Results, Provides Corporate Update Exhibit 99.1 Revance Reports Second Quarter 2022 Financial Results, Provides Corporate Update ?PDUFA date of September 8, 2022 for DaxibotulinumtoxinA for Injection in glabellar lines ?Reinspection of manufacturing facility completed as part of Class II BLA resubmission for DaxibotulinumtoxinA for Injection in glabellar lines ?Second quarter total revenue of $28.4 million, with RHA? Collection rev |
